Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis.

Sager RA, Woodford MR, Shapiro O, Mollapour M, Bratslavsky G.

Oncotarget. 2018 Apr 24;9(31):22220-22229. doi: 10.18632/oncotarget.25164. eCollection 2018 Apr 24.

2.

Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival.

Aleksic I, Rais-Bahrami S, Daugherty M, Agarwal PK, Vourganti S, Bratslavsky G.

Urol Ann. 2018 Apr-Jun;10(2):170-174. doi: 10.4103/UA.UA_136_17.

3.

Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.

Ghanie A, Formica MK, Wang D, Bratslavsky G, Stewart T.

Int Urol Nephrol. 2018 Feb;50(2):237-245. doi: 10.1007/s11255-017-1768-7. Epub 2017 Dec 15.

PMID:
29247309
4.

Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.

Dushukyan N, Dunn DM, Sager RA, Woodford MR, Loiselle DR, Daneshvar M, Baker-Williams AJ, Chisholm JD, Truman AW, Vaughan CK, Haystead TA, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2017 Nov 14;21(7):1883-1895. doi: 10.1016/j.celrep.2017.10.074.

5.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

6.

Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice.

Wang DC, Plante K, Stewart T, Wang D, Formica M, Daugherty M, Bratslavsky G.

Urol Oncol. 2017 Nov;35(11):660.e9-660.e15. doi: 10.1016/j.urolonc.2017.06.056. Epub 2017 Jul 20.

PMID:
28736248
7.

Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES.

Daugherty M, Chelluri R, Bratslavsky G, Byler T.

Int Urol Nephrol. 2017 Oct;49(10):1715-1721. doi: 10.1007/s11255-017-1660-5. Epub 2017 Jul 14.

PMID:
28710616
8.

Treatment trends, determinants, and survival of partial and radical nephrectomy for stage I renal cell carcinoma: results from the National Cancer Data Base, 2004-2013.

Plante K, Stewart TM, Wang D, Bratslavsky G, Formica M.

Int Urol Nephrol. 2017 Aug;49(8):1375-1381. doi: 10.1007/s11255-017-1612-0. Epub 2017 May 26.

PMID:
28550475
9.

Surgical Techniques in the Management of Small Renal Masses.

Daugherty M, Bratslavsky G.

Urol Clin North Am. 2017 May;44(2):233-242. doi: 10.1016/j.ucl.2016.12.009. Epub 2017 Mar 14. Review.

PMID:
28411915
10.

The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols.

Daugherty M, Sedaghatpour D, Shapiro O, Vourganti S, Kutikov A, Bratslavsky G.

Urol Oncol. 2017 Apr;35(4):153.e15-153.e20. doi: 10.1016/j.urolonc.2016.11.009. Epub 2017 Feb 12.

PMID:
28202224
11.

Pheochromocytoma in Urologic Practice.

Waingankar N, Bratslavsky G, Jimenez C, Russo P, Kutikov A.

Eur Urol Focus. 2016 Feb;1(3):231-240. doi: 10.1016/j.euf.2015.09.011. Epub 2016 Sep 28.

12.

Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print).

Watson MJ, Sidana A, Singer EA, Gupta GN, Rastinehad AR, Vourganti S, Bratslavsky G, Metwalli AR.

Int Urol Nephrol. 2017 Feb;49(2):267-268. doi: 10.1007/s11255-016-1433-6. Epub 2016 Oct 27. No abstract available.

PMID:
27812784
13.

Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.

Chelluri R, Caza T, Woodford MR, Reeder JE, Bratslavsky G, Byler T.

Anticancer Res. 2016 Oct;36(10):5079-5086.

PMID:
27798867
14.

Novel Concept and Method of Endoscopic Urethral Stricture Treatment Using Liquid Buccal Mucosal Graft.

Nikolavsky D, Manwaring J, Bratslavsky G, Caza T, Landas S, Hryniewicz-Jankowska A, Kotula L.

J Urol. 2016 Dec;196(6):1788-1795. doi: 10.1016/j.juro.2016.05.028. Epub 2016 May 10.

PMID:
27177425
15.

Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.

Watson MJ, Sidana A, Diaz AW, Siddiqui MM, Hankins RA, Bratslavsky G, Linehan WM, Metwalli AR.

J Endourol. 2016 Nov;30(11):1219-1226. Epub 2016 Oct 20.

16.

Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney.

Hankins RA, Walton-Diaz A, Truong H, Shih J, Bratslavsky G, Pinto PA, Marston Linehan W, Metwalli AR.

Int Urol Nephrol. 2016 Nov;48(11):1817-1821. Epub 2016 Aug 11.

17.

Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403-6.

Kutikov A, Uzzo RG, Smaldone MC, Haifler M, Bratslavsky G, Leibovich BC.

Eur Urol. 2017 Feb;71(2):e47-e48. doi: 10.1016/j.eururo.2016.07.011. Epub 2016 Jul 18. No abstract available.

PMID:
27436159
18.

The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M.

Nat Commun. 2016 Jun 29;7:12037. doi: 10.1038/ncomms12037.

19.

An Unusual Etiology of Urinary Retention - Small Cell Prostate Carcinoma.

Li G, Feng C, Zhou C, Bratslavsky G, Byler T.

Urol Case Rep. 2016 May 20;7:53-4. doi: 10.1016/j.eucr.2016.04.013. eCollection 2016 Jul.

20.

Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.

Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.

Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26. Review.

Supplemental Content

Loading ...
Support Center